Doubts about the possible clinical application of an anti-Pgp mAb based tumor therapy are related to the likely side effects that may arise as a result of either Pgp inhibition or ADCC, both exerted on cells expressing Pgp at physiological barriers of the body. This evidence concerns the gene PGP and neoplasm.